Clinical trials
Leiomyosarcoma trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 3 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 6 |
| Eli Lilly and Company | 2 |
| Grupo Espanol de Investigacion en Sarcomas | 2 |
| Igenomix | 2 |
| Advenchen Laboratories, LLC | 1 |
| Broto, Javier Martín, M.D. | 1 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1 |
| PTC Therapeutics | 1 |
| PharmaMar | 1 |
| Pierre Fabre Medicament | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leiomyosarcoma | 18 |
| Sarcoma | 11 |
| Liposarcoma | 9 |
| Histiocytoma, Malignant Fibrous | 7 |
| Sarcoma, Synovial | 7 |
| Hemangiosarcoma | 6 |
| Fibrosarcoma | 5 |
| Neurofibrosarcoma | 4 |
| Rhabdomyosarcoma | 4 |
| Sarcoma, Alveolar Soft Part | 4 |
Trials
Showing 26 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.